Amneal Pharmaceuticals

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

We recently published a list of Top 8 AI News Updates Investors Should Not Miss. In this article, we are going to take a look at where Nano-X Imaging Ltd. (NASDAQ:NNOX) stands against other top AI news updates investors should not miss.

HR technology company Phenom's new AI agents were designed in consideration of how roles can be different across various organizations.

The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.

Medical errors are the third leading cause of death in the U.S., contributing to over 250,000 preventable deaths each year. NeuralCure AI is tackling this crisis head-on by eliminating diagnostic blind spots and accelerating treatment precision with its cutting-edge AI-driven decision support system.

Verseon, a pioneering company in physics- and AI-powered drug discovery, revealed that its AI technology significantly outperforms Google's

Isomorphic was spun out of Google's AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up's potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.

Trained on large databases of brain data among newborns, CergenX's Wave device uses AI to help with earlier detection of brain injury.